The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy

被引:38
|
作者
Shiota, Masaki [1 ]
Yokomizo, Akira [1 ]
Takeuchi, Ario [1 ]
Imada, Kenjiro [1 ]
Kiyoshima, Keijiro [1 ]
Inokuchi, Junichi [1 ]
Tatsugami, Katsunori [1 ]
Naito, Seiji [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka 8128582, Japan
关键词
metabolic syndrome; prostate cancer; radical prostatectomy; risk factor; CANCER INCIDENCE; NATURAL-HISTORY; OBESITY; PREVALENCE; PROGRESSION; POPULATION; MORTALITY; ADULTS; CHOLESTEROL; AMERICAN;
D O I
10.1002/jso.23677
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objective To examine the association between the features of metabolic syndrome (MetS) (obesity, hypertension, diabetes mellitus, and dyslipidemia) and the risk of biochemical recurrence (BCR) after radical prostatectomy in patients with prostate cancer. Methods This study included 283 Japanese patients with localized prostate cancer who were treated with radical prostatectomy between 2008 and 2012. Their oncological outcomes and the prognostic significance of several clinicopathological factors, as well as the features of MetS, were analyzed. Results Of 283 men who underwent radical prostatectomy, 49 (17.2%) subsequently developed BCR with a median postoperative follow-up of 14.8 months. Among the clinicopathological factors, prostate-specific antigen (PSA) level at diagnosis, pathological stage, pathological Gleason score, and lymph-node involvement were independent risk factors for BCR in multivariate analysis. In addition, the number of metabolic risk factors was also an independent risk factor for BCR. Conclusions The features of MetS were linked with poorer outcome after radical prostatectomy among Japanese men. Further investigations are needed to determine the effect of improving MetS on prostate cancer prognosis. J. Surg. Oncol. 2014; 110:476-481. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:476 / 481
页数:6
相关论文
共 50 条
  • [31] Short (≤1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
    Shikanov, Sergey
    Marchetti, Pablo
    Desai, Vikas
    Razmaria, Aria
    Antic, Tatjana
    Al-Ahmadie, Hikmat
    Zagaja, Gregory
    Eggener, Scott
    Brendler, Charles
    Shalhav, Arieh
    BJU INTERNATIONAL, 2013, 111 (04) : 559 - 563
  • [32] Statin use and risk of prostate cancer biochemical recurrence after radical prostatectomy
    Prabhu, Nicole
    Kapur, Navina
    Catalona, William
    Leikin, Robin
    Helenowski, Irene
    Jovanovich, Borko
    Gurley, Michael
    Okwuosa, Tochi M.
    Kuzel, Timothy M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (02) : 130.e9 - 130.e15
  • [33] Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy
    Briganti, Alberto
    Karnes, R. Jeffrey
    Joniau, Steven
    Boorjian, Stephen A.
    Cozzarini, Cesare
    Gandaglia, Giorgio
    Hinkelbein, Wolfgang
    Haustermans, Karin
    Tombal, Bertrand
    Shariat, Shahrokh
    Sun, Maxine
    Karakiewicz, Pierre I.
    Montorsi, Francesco
    Van Poppel, Hein
    Wiegel, Thomas
    EUROPEAN UROLOGY, 2014, 66 (03) : 479 - 486
  • [34] Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy
    Georg Müller
    Malte Rieken
    Gernot Bonkat
    Joel Roman Gsponer
    Tatjana Vlajnic
    Christian Wetterauer
    Thomas C. Gasser
    Stephen F. Wyler
    Alexander Bachmann
    Lukas Bubendorf
    Virchows Archiv, 2014, 465 : 429 - 437
  • [35] Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy
    Mueller, Georg
    Rieken, Malte
    Bonkat, Gernot
    Gsponer, Joel Roman
    Vlajnic, Tatjana
    Wetterauer, Christian
    Gasser, Thomas C.
    Wyler, Stephen F.
    Bachmann, Alexander
    Bubendorf, Lukas
    VIRCHOWS ARCHIV, 2014, 465 (04) : 429 - 437
  • [36] Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
    Flores, Jose M.
    Vertosick, Emily
    Jenkins, Lawrence C.
    Cooper, John
    Benfante, Nicole
    Sjoberg, Daniel
    Vickers, Andrew J.
    Eastham, James A.
    Laudone, Vincent P.
    Scardino, Peter T.
    Nelson, Christian J.
    Mulhall, John P.
    JOURNAL OF UROLOGY, 2024, 211 (03) : 400 - 406
  • [37] Risk factors for biochemical recurrence after robotic assisted radical prostatectomy: a single surgeon experience
    Tanimoto, Ryuta
    Fashola, Yomi
    Scotland, Kymora B.
    Calvaresi, Anne E.
    Gomella, Leonard G.
    Trabulsi, Edouard J.
    Lallas, Costas D.
    BMC UROLOGY, 2015, 15
  • [38] Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy
    Morlacco, Alessandro
    Dal Moro, Fabrizio
    Rangel, Laureano J.
    Carlson, Rachel E.
    Schulte, Phillip J.
    Jeffrey, Karnes R.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (12) : 528.e1 - 528.e6
  • [39] Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy
    van Roermund, Joep G. H.
    Kok, Dieuwertje E. G.
    Wildhagen, Mark F.
    Kiemeney, Lambertus A.
    Struik, Femke
    Sloot, Sarah
    van Oort, Inge M.
    Hulsbergen-van de Kaa, Christina A.
    van Leenders, Geert J. L. H.
    Bangma, Chris H.
    Witjes, J. Alfred
    BJU INTERNATIONAL, 2009, 104 (03) : 321 - 325
  • [40] Hormonal treatment in biochemical recurrence after radical prostatectomy
    Rodriguez Antolin, Alfredo
    Duarte Ojeda, Jose Manuel
    Romero Otero, Javier
    Cabeza Rodriguez, Angeles
    Castellano, Daniel
    Dominguez Esteban, Mario
    Diez Sicilia, Laura
    Diaz Gonzalez, Rafael
    ARCHIVOS ESPANOLES DE UROLOGIA, 2012, 65 (01): : 111 - 121